Background-We studied whether inflammation after myocardial infarction (MI) is a risk factor for recurrent coronary events and whether randomized treatment with pravastatin reduces that risk. Methods and Results-A nested case-control design was used to compare C-reactive protein (CRP) and serum amyloid A (SAA) levels in prerandomization blood samples from 391 participants in the Cholesterol and Recurrent Events (CARE) trial who subsequently developed recurrent nonfatal MI or a fatal coronary event (cases) and from an equal number of age-and sex-matched participants who remained free of these events during follow-up (control subjects). Overall, CRP and SAA were higher among cases than control subjects (for CRP Pϭ0.05; for SAA Pϭ0.006) such that those with levels in the highest quintile had a relative risk (RR) of recurrent events 75% higher than those with levels in the lowest quintile (for CRP RRϭ1.77, Pϭ0.02; for SAA RRϭ1.74, Pϭ0.02). The study group with the highest risk was that with consistent evidence of inflammation (elevation of both CRP and SAA) who were randomly assigned to placebo (RRϭ2.81, Pϭ0.007); this risk estimate was greater than the product of the individual risks associated with inflammation or placebo assignment alone. In stratified analyses, the association between inflammation and risk was significant among those randomized to placebo (RRϭ2.11, Pϭ0.048) but was attenuated and nonsignificant among those randomized to pravastatin (RRϭ1.29, Pϭ0.5). Conclusions-Evidence of inflammation after MI is associated with increased risk of recurrent coronary events. Therapy with pravastatin may decrease this risk, an observation consistent with a nonlipid effect of this agent. (Circulation. 1998;98:839-844.)
A lthough basic laboratory research indicates that several components of the inflammatory response are associated with the initiation and progression of atherosclerosis, 1, 2 clinical data relating inflammation to risks of future coronary events are sparse. In this regard, recent prospective data demonstrate that low-grade inflammation as assessed by C-reactive protein (CRP) predicts risk of first myocardial infarction and other atherosclerotic events among apparently healthy middle-aged men. [3] [4] [5] In addition, CRP appears to predict risks of infarction and coronary death among highrisk patients 6, 7 as well as ischemic complications among those with stable and unstable angina. 8 -10 However, whether markers of inflammation such as CRP and serum amyloid A (SAA) predict risk of recurrent coronary events among stable patients with a prior history of myocardial infarction has not been evaluated. Furthermore, although aspirin may modify the effects of inflammation on coronary risk, 3 it is unknown whether other preventive agents might also have differential effects among those with and without evidence of inflammation.
To address these issues, we measured 2 serum markers of inflammation, CRP and SAA, among postmyocardial infarction patients enrolled in the Cholesterol and Recurrent Events (CARE) trial who were prospectively followed for incident events of recurrent myocardial infarction and coronary death. 11 As the CARE trial randomized participants between 40 mg of pravastatin per day and placebo, we were afforded the additional unique opportunity to evaluate directly whether any association between markers of inflammation and risk of recurrent coronary events might be affected by the use of this 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.
Methods
The CARE trial was a randomized, double-blind, placebo-controlled trial of 40 mg pravastatin per day in the secondary prevention of cardiovascular disease among 4159 patients with a prior history of myocardial infarction who had total cholesterol levels Ͻ240 mg/dL and LDL cholesterol levels between 115 and 175 mg/dL. 11 Patients were eligible for inclusion if they had had an acute myocardial infarction between 3 and 20 months before randomization, were 21 to 75 years of age, had left ventricular ejection fraction of not Ͻ25%, and no evidence of congestive heart failure. The primary end point of the CARE trial was death from coronary heart disease (including fatal myocardial infarction, either definite or probable; sudden death; death during a coronary intervention; and death from other coronary causes) or a symptomatic (unless during noncardiac surgery) nonfatal myocardial infarction confirmed by serum creatine kinase measurements.
Blood samples were collected in the CARE trial during prerandomization clinic visits designed in part to determine baseline lipid levels for study eligibility. On average, these visits occurred 8.9 months after the qualifying acute myocardial infarction. Samples were collected in EDTA, shipped to a central collection site on cooled gel packs, and frozen at Ϫ80°C for future analyses. Details of the blood collection and storage procedures used in the CARE trial are outlined elsewhere. 12 For this analysis, prerandomization blood samples were assayed for CRP and SAA among 391 study participants who subsequently developed recurrent myocardial infarction or death from coronary heart disease (cases), and among an equal number of age-and sex-matched study participants who remained free of these recurrent coronary events during a follow-up period lasting 5 years (control subjects). High sensitivity assays for CRP and SAA were performed according to methods described by the manufacturer (Behring Diagnostics). 13, 14 Case and control blood specimens were assayed in blinded pairs with the position of the case specimen varied at random within the pairs to reduce the possibility of systematic bias and decrease interassay variability. Laboratory investigators were unaware of case or control status.
Means or proportions for baseline risk factors were computed for the case and control subjects, and the significance of any differences in means tested with the Student's t test; differences in proportions were tested with the 2 statistic. Because the distributions of both CRP and SAA are rightward skewed, median concentrations were computed for these parameters and the significance of any differences between cases and control subjects assessed using the Wilcoxon rank-sum test. Mean concentrations of both CRP and SAA were also computed after log transformation that resulted in nearly normal distributions.
Tests for trend were used to assess for any relation of increasing CRP or SAA values and the risk of recurrent coronary events after dividing the study sample into quintiles defined by the distribution of the control values. Risk estimates and confidence intervals were obtained with the use of conditional logistic regression analyses. To assess for nonlinear effects, we further evaluated for evidence of association between CRP or SAA and recurrent coronary events among patients with baseline levels of each inflammatory parameter Ն25th, 50th, 75th, 90th, and 95th percentile cut points as defined by the control values. Adjusted estimates of risk were obtained with conditional logistic regression models that accounted for the matching variables of age and sex and that controlled for smoking status (past, former, current) and for baseline levels of LDL cholesterol, HDL cholesterol, and triglycerides.
To examine the influence of pravastatin among those with and those without serum markers of inflammation, we classified study patients into 2 groups, those with consistent evidence of inflammation (defined as having both CRP and SAA greater than or equal to the respective 90th percentile cut points) and those without consistent evidence of inflammation (defined as having both CRP and SAA below the respective 90th percentile cut points). Logistic regression analyses were then used to evaluate the risks of recurrent coronary events among those with and those without inflammation who were randomly assigned either to pravastatin or placebo. All P values are 2-tailed and confidence intervals calculated at the 95% level. Table 1 shows baseline clinical characteristics of the study participants. By matching, case and control subjects were similar in age and sex. Other baseline characteristics of the study participants are similar to those reported for the CARE trial as a whole. 11 At study entry, 83% of patients reported aspirin use.
Results
Overall, median plasma concentrations of both CRP and SAA before randomization were significantly higher among those in whom coronary events subsequently developed than among those who remained free of recurrent disease (for CRP Pϭ0.05, for SAA Pϭ0.006) ( Table 2) .
In analyses evaluating for evidence of association between increasing levels of CRP or SAA and recurrent coronary events, statistically significant trends were observed across quintiles of both parameters (for CRP P-trendϭ0.044; for SAA P-trendϭ0.006). As shown in Table 3 and Figures 1 and To explore further the apparent nonlinearity of the relation between CRP and SAA and recurrent coronary events, relative risks were computed for a series of cut points based on the control distribution (Tables 4 and 5 ). In these analyses, the relative risks associated with prerandomization CRP concentrations equal to or greater than the 25th, 50th, 75th, 90th, and 95th percentiles of the control distribution were 1.2 (Pϭ0.2), 1.2 (Pϭ0.2), 1.3 (Pϭ0.08), 1.6 (Pϭ0.03), and 1.9 (Pϭ0.02). Similarly, the relative risks associated with prerandomization SAA concentrations exceeding the 25th, 50th, 75th, 90th, and 95th percentiles of the control distribution were 1.2 (Pϭ0.2), 1.5 (Pϭ0.01), 1.5 (Pϭ0.02), 1.6 (Pϭ0.03), and 1.7 (Pϭ0.07). As also shown in Tables 4 and  5 , these risk estimates were not materially altered in analyses controlling for smoking status or for LDL cholesterol, HDL cholesterol, or triglycerides. Further adjustment for other risk factors including diabetes had minimal impact on these risk estimates.
Log-normalized prerandomization concentrations of CRP and SAA were highly correlated (rϭ0.67, PϽ0.001). Furthermore, 708 of the 782 study participants (91%) had concordant evidence regarding the presence (or absence) of low-grade inflammation in that their plasma levels of both CRP and SAA were consistently above (or below) the 90th percentile cut points for each parameter. To investigate for evidence of an interrelation between inflammation and pravastatin, we divided these 708 study subjects with concordant CRP and SAA levels into 4 groups on the basis of the presence or absence of high levels of both markers and on randomization to either pravastatin or placebo. As shown in Figure 3 , a statistically significant increase in risk of recurrent coronary events was observed across these 4 study groups (Ptrendϭ0.005). Specifically, compared with the lowest risk group (those with both markers of inflammation below the 90th percentile who were randomly assigned to pravastatin), the group with the highest risk of recurrent events were those with levels of both CRP and SAA equal to or greater than the 90th percentile who were randomly assigned to placebo (RRϭ2.8, 95% confidence interval [CI] 1.3 to 6.0, Pϭ0.007). This risk estimate was greater than the product of the individual risks associated with evidence of either inflammation (RRϭ1.3) or placebo assignment (RRϭ1.3) alone (Figure 3 ). Results were similar in analyses based solely on elevations of CRP or based solely on elevations of SAA. Furthermore, in analyses stratified by treatment assignment, the association between concordant serum evidence of inflammation and coronary risk was statistically significant among those randomized to placebo (RRϭ2.11, Pϭ0.048) but was attenuated and no longer significant among those randomized to pravastatin (RRϭ1.29, Pϭ0.5). Finally, among the 708 patients who had concordant results for both inflammatory markers, randomized treatment with pravastatin reduced the risk of recurrent MI or coronary death by 28% (Pϭ0.03), a finding similar to that in the CARE study as a whole (risk reductionϭ24%, Pϭ0.003). 9 Among those with evidence of inflammation, the proportion of recurrent coronary events prevented by pravastatin was 54% compared with 25% among those without inflammation, even though baseline levels of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides were virtually identical in comparisons of those with and those without evidence of inflammation (Table 6 ).
Discussion
These prospective data indicate that plasma concentration of 2 markers of inflammation, CRP and SAA, predict the risk of recurrent coronary events among stable patients with a prior history of myocardial infarction. In these data, the risk of recurrent coronary events associated with elevations of CRP or SAA was independent of smoking status and baseline levels of LDL cholesterol, HDL cholesterol, and triglycerides. These data also raise the possibility of an interrelation between serum evidence of inflammation, pravastatin, and coronary risk. Specifically, the magnitude of the risk of recurrent coronary events observed among those with evidence of inflammation who were randomly assigned to placebo (RRϭ2.81, Pϭ0.007) was greater than the product of the observed risks associated with either inflammation alone or placebo assignment alone. Moreover, while a statistically significant association was observed between evidence of inflammation and coronary events among those assigned to placebo, this risk was attenuated and no longer significant among those assigned to pravastatin.
The current data describing the predictive value of CRP among patients with prior myocardial infarction extends recent observations that CRP predicts risk of coronary disease among apparently healthy individuals [3] [4] [5] [6] as well as those at high risk because of smoking 7 and among patients with stable and unstable angina. 8 -10 Moreover, the current data for SAA indicate that a second marker of inflammation is also predictive of future cardiovascular risk. This observation suggests that the associations noted are more likely due to inflammation than to any direct effect of either CRP or SAA. In this regard, the current findings conflict with data describing no association between SAA and vascular risk in one recent study of patients with stable and unstable angina. 9 The finding that the effect of inflammation on risk was attenuated and no longer statistically significant among pa- tients randomly assigned to pravastatin raises several intriguing issues. For example, it is possible that the clinical benefits of lipid reduction with pravastatin in the presence of inflammation are greater than in its absence. However, as baseline lipid levels were virtually identical among those with and those without evidence of inflammation (and among those randomly assigned to pravastatin as compared with placebo), it seems unlikely that this effect is due to lipid lowering alone. Thus it is tempting to speculate that nonlipid effects of pravastatin may be responsible for the current observations. 15, 16 With specific regard to the inflammatory process, experimental studies suggest that pravastatin inhibits endogenous cholesterol synthesis in macrophages, 17 a process with the potential to reduce macrophage activation and foam cell formation. 15 Other hypothesized nonlipid effects of pravastatin and other HMG-CoA reductase inhibitors include modulation of immune function in vitro, 15, 18 antiproliferative effects on vascular smooth muscle, 19 -21 and antithrombotic properties. [22] [23] [24] [25] Finally, several studies demonstrate that endothelial function and coronary vasomotion improve with the use of HMG-CoA reductase inhibitors including pravastatin. 26 -30 Potential limitations of these data merit consideration. Because cigarette consumption increases levels of both CRP and SAA, it is possible that our results reflect confounding by this factor. However, as demonstrated in the multivariate analyses, adjustment for smoking had no effect on the point estimates of risk observed. We further believe it unlikely that our results reflect ongoing subclinical ischemia, which might have led to inadvertent elevations of both CRP and SAA. In this regard, the levels of CRP and SAA described in these data are substantially below those typically associated with the acute-phase response. 31, 32 Furthermore, prior data indicate that elevations of CRP and SAA associated with acute myocardial infarction return to baseline within 8 to 10 days. 31, 33, 34 Because blood samples in our study were obtained a minimum of 3 months after the qualifying myocardial infarction occurred (mean 8.9 months), inadvertent bias on this basis seems unlikely.
We believe these data support 3 main conclusions. First, plasma concentrations of CRP and SAA both appear to predict the risk of recurrent coronary events among stable patients with a history of prior myocardial infarction. As such, these data suggest that markers of inflammation may provide a mechanism to stratify postinfarction patients into relatively high-risk and low-risk groups. Second, because both CRP and SAA appeared equally predictive of risk and were highly correlated with each other, these data suggest that the associations noted are not a direct effect of either of these proteins but rather are a reflection of underlying systemic inflammation. 35 Finally, these data raise the possibility that the effect of inflammation on coronary risk may be attenuated by pravastatin therapy. Thus these data also raise the intriguing possibility that the efficacy of pravastatin may result in part from anti-inflammatory as well as lipid-lowering properties. 
